◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Syncom Formulations (India) Limited (SYNCOMF) Financial History

Name: Syncom Formulations (India) Limited (SYNCOMF) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Syncom Formulations (India) Limited (SYNCOMF) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Indore, India with about 902 employees. Its market capitalization is roughly ₹19 billion. In the fiscal year ended 2026-03-31, SYNCOMF reported ₹4.8B in revenue and ₹764M in net income.

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments.

Interactive charts & full statements →

SYNCOMF Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹4.8B	₹4.6B	₹2.6B	₹2.2B
Gross Profit	₹1.9B	₹1.4B	₹942M	₹726M
Operating Income (EBIT)	₹777M	₹542M	₹252M	₹164M
Net Income	₹764M	₹494M	₹253M	₹201M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYNCOMF Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹1.3B	₹1.4B	₹1.2B	₹1.2B	₹1.2B	—
Gross Profit	₹597M	₹521M	₹541M	₹510M	₹477M	—
Operating Income (EBIT)	₹247M	₹195M	₹198M	₹170M	₹145M	—
Net Income	₹248M	₹252M	₹189M	₹166M	₹158M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYNCOMF Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	—	—	—	(₹28M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYNCOMF Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹5.3B	₹4.1B	₹4.0B	₹3.8B	—
Total Liabilities	₹1.2B	₹711M	₹1.2B	₹1.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SYNCOMF viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

6887 · Sunshine Lake Pharma Co., Ltd. — HK$21 billion
2929 · Pharma Foods International Co., Ltd. — JPY 21 billion
VENUSREM · Venus Remedies Limited — ₹21 billion
4538 · Fuso Pharmaceutical Industries,Ltd. — JPY 19 billion
0013 · HUTCHMED (China) Limited — HK$19 billion
HESTERBIO · Hester Biosciences Limited — ₹19 billion
1513 · Livzon Pharmaceutical Group Inc. — HK$18 billion
0512 · Grand Pharmaceutical Group Limited — HK$17 billion

← SYNC All “S” companies SYNEX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.